- Home
- SPRB vs EQ Comparison
SPRB vs EQ Comparison
Compare SPRB & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRB
- EQ
- Stock Information
- Founded
- SPRB 2014
- EQ 2017
- Country
- SPRB United States
- EQ United States
- Employees
- SPRB N/A
- EQ N/A
- Industry
- SPRB Medicinal Chemicals and Botanical Products
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- SPRB Health Care
- EQ Health Care
- Exchange
- SPRB Nasdaq
- EQ Nasdaq
- Market Cap
- SPRB 22.8M
- EQ 24.8M
- IPO Year
- SPRB 2020
- EQ 2018
- Fundamental
- Price
- SPRB $0.38
- EQ $0.65
- Analyst Decision
- SPRB Hold
- EQ Buy
- Analyst Count
- SPRB 7
- EQ 2
- Target Price
- SPRB $2.17
- EQ $5.00
- AVG Volume (30 Days)
- SPRB 870.1K
- EQ 106.8K
- Earning Date
- SPRB 11-11-2024
- EQ 11-13-2024
- Dividend Yield
- SPRB N/A
- EQ N/A
- EPS Growth
- SPRB N/A
- EQ N/A
- EPS
- SPRB N/A
- EQ N/A
- Revenue
- SPRB $7,101,000.00
- EQ $45,914,000.00
- Revenue This Year
- SPRB N/A
- EQ $4.76
- Revenue Next Year
- SPRB N/A
- EQ N/A
- P/E Ratio
- SPRB N/A
- EQ N/A
- Revenue Growth
- SPRB N/A
- EQ 7.70
- 52 Week Low
- SPRB $0.37
- EQ $0.60
- 52 Week High
- SPRB $5.95
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- SPRB 31.70
- EQ 38.13
- Support Level
- SPRB $0.37
- EQ $0.63
- Resistance Level
- SPRB $0.42
- EQ $0.74
- Average True Range (ATR)
- SPRB 0.04
- EQ 0.05
- MACD
- SPRB -0.01
- EQ 0.00
- Stochastic Oscillator
- SPRB 5.93
- EQ 13.40
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.